Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90

International Journal of Molecular Medicine

Volumn 27, Issue 3, 2011, Pages 441-446

  Lee, Ji Hyun ^a,b   Choi, Kyu Jin ^a   Seo, Woo Duck ^a,c   Jang, Soon Young ^a   Kim, Mira ^a   Lee, Byong Won ^c   Kim, Jun Young ^c   Kang, Seongman ^b   Park, Ki Hun ^d   Lee, Yun Sil ^a   Bae, Sangwoo ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea University   (South Korea)

^c National Institute of Animal Science   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

Celastrol; Client proteins; Hsp90; p53; Radiation sensitivity

Indexed keywords

6BETA ACETONYL 22BETA HYDROXYTINGENOL; ADENOSINE TRIPHOSPHATE; CELASTROL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEASOME; PROTEIN P53; SERINE; SURVIVIN; TRITERPENOID; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CELL KILLING; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION;

CELL LINE, TUMOR; GAMMA RAYS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79551598917     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.601     Document Type: Article

References (22)

1. Tofilon PJ and Camphausen K: Molecular targets for tumor radiosensitization. Chem Rev 109: 2974-2988, 2009.
2. Camphausen K and Tofilon PJ: Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 13: 4326-4330, 2007
3. Salminen A, Lehtonen M, Paimela T and Kaarniranta K: Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394: 439-442, 2010.
4. Sethi G, Ahn KS, Pandey MK and Aggarwal BB: Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109: 2727-2735, 2007
5. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS and Lee JJ: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72: 1311-1321, 2006.
6. Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, Lu W, Yang B and He QJ: Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 28: 23-32, 2010.
7. Zhang T, Li Y, Yu Y, Zou P Jiang Y and Sun D: Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 284: 35381-35389, 2009.
8. Sharp S and Workman P: Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95: 323-348, 2006.
9. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG and Sun D: A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170, 2008
10. Yang H, Chen D, Cui QC, Yuan X and Dou QP: Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine', is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765, 2006.
11. Ngassapa O, Soejarto DD, Pezzuto JM and Farnsworth NR: Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea. J Nat Prod 57: 1-8, 1994.
12. Chung HJ, Yoon SI, Shin SH, Koh YA, Lee SJ, Lee YS and Bae S: p53-Mediated enhancement of radiosensitivity by selenophosphate synthetase 1 overexpression. J Cell Physiol 209: 131-141, 2006.
13. Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS and Lee SJ: Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 278: 50624-50634, 2003.
14. Russell JS, Burgan W, Oswald KA, Camphausen K and Tofilon PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9: 3749-3755, 2003.
15. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M and Hallahan DE: Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64: 2840-2845, 2004. (Pubitemid 38500623)
16. Petronelli A, Pannitteri G and Testa U: Triterpenoids as new promising anticancer drugs. Anticancer Drugs 20: 880-892, 2009.
17. Sharma V, Hupp CD and Tepe JJ: Enhancement of chemotherapeutic efficacy by small molecule inhibition of NF-kappaB and checkpoint kinases. Curr Med Chem 14: 1061-1074, 2007
18. Dote H, Burgan WE, Camphausen K and Tofilon PJ: Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 66: 9211-9220, 2006.
19. Gudkov AV and Komarova EA: The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3: 117-129, 2003.
20. Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
21. Zhang D, Zaugg K, Mak TW and Elledge SJ: A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 126: 529-542, 2006.
22. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS and Xu L: Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 74: 1217-1225, 2009.